Adult-use cannabis legalization in the U.S. has generated billions in tax revenue for the states that have passed the reforms.

MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.

There’s a psychedelic revolution on the horizon that could change mental health treatment.

Cybin’s 12th patent application further supports the company’s novel molecule development.

A Texas Senate committee on Wednesday unanimously approved a House-passed bill that would require the state to conduct a study into the therapeutic potential of psychedelics like psilocybin and MDMA.

Wesana’s new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.

Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.

Mindmed’s drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.

MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.

Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache.